Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic–Baltic–British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.

St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers analysis to compare the safety and efficacy of biodegradable polymer stents (BP-DES) to the durable polymer Resolute Integrity drug-eluting stent (DP-DES) from Medtronic. At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity.

Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early feasibility study, showing improved hemodynamics from baseline and consistent valve performance at one year. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, the positive new data from the first-of-its-kind early feasibility study led the U.S. Food and Drug Administration (FDA) to also recently approve the initiation of a Pivotal Investigational Device Exemption (IDE) study to evaluate the valve’s safety and effectiveness.

St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the Amplatzer PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO). With the approval, patients in the United States with a PFO (a small opening between the upper chambers of the heart) who have suffered an ischemic stroke — a stroke resulting from blockages in the blood supply to the brain — will now have access to a closure device proven to reduce their risk of recurrent stroke, rather than relying on medical management alone.

Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission tomography (PET)/computed tomography (CT) activity-based probe to detect atherosclerotic plaques. The study is published in the October issue of The Journal of Nuclear Medicine.

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, held Oct. 29-Nov. 3 in Washington, D.C.

Edwards Lifesciences Corp. announced new five-year hemodynamic data from the PARTNER Trial demonstrating excellent durability of the first-generation Edwards Sapien transcatheter heart valve (THV). This evaluation of 2,404 patients, encompassing 10,560 echoes and 6,493 patient years of follow-up, is the largest core lab based study of transcatheter heart valves to date.

Medtronic plc presented new positive data from two large registries aimed at evaluating 30-day clinical performance outcomes for the self-expanding, recapturable and repositionable CoreValve Evolut R System in “real-world” severe aortic stenosis patient populations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now